Interleukin-6 (IL-6) treatment can enhance anoikis resistance by phosphorylating STAT3, while STAT3 inhibitors like piperlongumine can induce anoikis and prevent tumor formation and metastasis in pancreatic cancer models [242]. Here, IL6 is linked to familial pancreatic carcinoma.